<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192140</url>
  </required_header>
  <id_info>
    <org_study_id>FM026</org_study_id>
    <nct_id>NCT00192140</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age</brief_title>
  <official_title>An Open-Label, Single-Arm Trial to Assess the Shedding, Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To describe the proportion of individuals 5-49 years of age who shed vaccine strain
           viruses.

        -  To describe the duration of shedding of vaccine viruses in individuals 5-49 years of
           age.

        -  To describe the genotypic and phenotypic stability of shed vaccine viruses.

        -  To describe the immune responses of FluMist in individuals 5-49 years of age.

        -  To describe the safety of FluMist in individuals 5-49 years of age in relation to
           shedding and the immune response
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the viral shedding, immunogenicity and safety of
      FluMist when administered to healthy individuals between 5-49 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses.</measure>
    <time_frame>28 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.</measure>
    <time_frame>28 days after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the immune responses of FluMist in indivduals 5-49 years of age.</measure>
    <time_frame>28 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response.</measure>
    <time_frame>28 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment>345</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FluMist</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist</intervention_name>
    <description>A single intranasal dose of FluMist will be administered to approx. 300 subjects.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  5-49 years of age;

          -  In good health;

          -  Individual or parent/guardian available by telephone;

          -  Ability of the participant or parent/guardian to understand and comply with the
             requirements of the protocol; and

          -  Signed informed consent and HIPAA authorization by the participant or parent/guardian.

        Exclusion Criteria:

          -  History of hypersensitivity to any component of FluMist, including egg or egg
             products;

          -  History of hypersensitivity to gentamicin;

          -  Close contact who is immunocompromised within the same household;

          -  Known or suspected immune deficiency diseases or immunosuppressed or have altered or
             compromised immune status as a consequence of treatment with immunosuppressive
             therapies;

          -  History of chronic underlying medical conditions such as chronic disorders of the
             cardiovascular and pulmonary systems, chronic metabolic diseases (including diabetes),
             renal dysfunction, or hemoglobinopathies;

          -  History of Guillain-Barré syndrome;

          -  History of asthma or reactive airways disease;

          -  Acute febrile (&gt;100.0°F oral) and/or respiratory illness, within the 72 hours prior to
             enrollment;

          -  For children and adolescents - use of aspirin or aspirin containing products in the
             month prior to enrollment or anticipated use during the study;

          -  Pregnancy or, in biologically capable women (e.g., menses within the last year), not
             willing to agree to acceptable birth control for three months after enrolling into the
             study (for those biologically capable, a urine pregnancy test must be performed on the
             day of vaccination with a negative result);

          -  Administration of any intranasal medication within two weeks prior to enrollment or
             expected receipt during this study;

          -  Administration of any live virus vaccine within one month prior to enrollment or if
             receipt of another live virus vaccine is expected within one month of the vaccination
             in this study;

          -  Administration of any inactivated vaccine within two weeks prior to enrollment or if
             receipt of another inactivated vaccine is expected within two weeks of the vaccination
             in this study;

          -  Participation in another investigational trial or administration of any
             investigational drug within one month prior to enrollment or during this study;

          -  Employees of the research center, any individuals involved with the conduct of the
             study, or any family member of such individuals;

          -  Laboratory confirmed influenza (positive culture or rapid antigen test) in the prior
             influenza season (2003/2004 or 2004/2005 season);

          -  Receipt of any influenza vaccine in the prior influenza season; and

          -  Any condition that in the opinion of the investigator would interfere with the
             interpretation or evaluation of the vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC International, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric / Adult Research, Inc</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Vaccine Development</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Clinical Trials International</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physician's Research Inc.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center North</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia, Elson Student Health Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshall University Medical Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>December 27, 2007</last_update_submitted>
  <last_update_submitted_qc>December 27, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2007</last_update_posted>
  <responsible_party>
    <name_title>Chris Ambrose, Dir. Medical Affairs</name_title>
    <organization>MedImmune Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

